Keyphrases
Left Ventricular Assist Device
69%
Heart Failure
48%
Acute Decompensated Heart Failure
39%
Acute Heart Failure
32%
Patients with Heart Failure
26%
Left Ventricular Assist Device Implantation
25%
Heart Failure with Preserved Ejection Fraction (HFpEF)
24%
Sacubitril-valsartan
24%
Risk Score
19%
Orthotopic Heart Transplantation
17%
Bleeding
17%
Heart Transplant
15%
Continuous-flow Left Ventricular Assist Device (CF-LVAD)
14%
HeartMate 3
13%
Reduced Ejection Fraction
13%
Heart Failure Hospitalization
13%
Right Ventricular Function
12%
Decongestion
12%
Driveline
11%
Heart Transplantation
11%
End-stage Heart Failure
11%
HeartMate
10%
Randomized Clinical Trial
10%
International Normalized Ratio
10%
Ventricular Assist Device Infection
10%
Optimization Strategy
10%
Non-associated
10%
Clinical Outcomes
9%
HeartMate II
9%
Heart Failure Trials
9%
Confidence Interval
9%
Weight Loss
9%
Adjusted Odds Ratio
9%
Treatment Strategy
9%
Hospitalization
8%
Hazard Ratio
8%
Strategy Evaluation
8%
Angiotensin Receptor-neprilysin Inhibitor
8%
Diuretics
8%
Comorbidity
8%
Tolerability
8%
Readmission
8%
Congestion
8%
Cardiorenal
8%
Chronic Heart Failure
7%
Left Ventricular Assist Device Support
7%
Causes of Readmission
6%
Heart Failure Care
6%
Left Ventricular Assist Device Therapy
6%
Right Ventricular
6%
Medicine and Dentistry
Left Ventricular Assist Device
100%
Congestive Heart Failure
68%
Acute Decompensated Heart Failure
31%
Heart Graft
26%
Infection
19%
Heart Transplantation
15%
Bleeding
14%
Heart Right Ventricle Failure
12%
Odds Ratio
12%
Assisted Circulation
11%
Implant
10%
Heart Failure with Preserved Ejection Fraction
10%
Device Infection
10%
Diuretics
8%
Hazard Ratio
8%
Cardiovascular System
8%
Myocardial Disease
8%
Comorbidity
7%
Apoplexy
7%
Quality of Life
7%
Diabetes
7%
Frailty
6%
Cohort Effect
6%
Messenger RNA
6%
Ejection Fraction
6%
Device Therapy
6%
Antibody Mediated Rejection
6%
Clinical Significance
6%
Biological Marker
6%
Outpatient
5%
Sodium Bicarbonate
5%
Systolic Blood Pressure
5%
Cardiotoxicity
5%
Sepsis
5%
Angiotensin Receptor Antagonist
5%
Soft Tissue Sarcoma
5%
Tertiary Care
5%
Antibiotic Therapy
5%
COVID-19
5%
Fluorescence in Situ Hybridization
5%
Dexrazoxane
5%
Acute Myeloid Leukemia
5%
Whole Genome Sequencing
5%
Angiotensin II
5%
Anticoagulation
5%
Clinical Prediction Rule
5%
Renin Angiotensin Aldosterone System
5%
Acute Heart Infarction
5%
Model for End-Stage Liver Disease
5%
Recurrent Disease
5%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
79%
Acute Heart Failure
27%
Valsartan/Sacubitril
26%
Bleeding
12%
Comorbidity
11%
Heart Failure with Preserved Ejection Fraction
11%
Randomized Clinical Trial
10%
Myocardial Disease
8%
Enkephalinase Inhibitor
8%
Heart Failure with Reduced Ejection Fraction
7%
Cerebrovascular Accident
7%
Tolerability
7%
Frailty
6%
Dicarbonate
5%
Brain Hemorrhage
5%
Angiotensin
5%
Renin
5%
Biological Marker
5%
Brain Natriuretic Peptide
5%
Doxorubicin
5%
Soft Tissue Sarcoma
5%
Antidepressant
5%
Olaratumab
5%
Razoxane
5%
Thrombosis
5%
Bosentan
5%
Aldosterone
5%
Acute Heart Infarction
5%
Liraglutide
5%
Serum Albumin
5%
Pulmonary Hypertension
5%
Sepsis
5%
Membrane Metalloendopeptidase
5%
Messenger RNA
5%